HDAC4/HDAC5/HDAC9 Antikörper
-
- Target Alle HDAC4/HDAC5/HDAC9 Produkte
- HDAC4/HDAC5/HDAC9 (HDAC4,HDAC5,HDAC9)
-
Reaktivität
- Human
-
Wirt
- Kaninchen
-
Klonalität
- Polyklonal
-
Konjugat
- Dieser HDAC4/HDAC5/HDAC9 Antikörper ist unkonjugiert
-
Applikation
- Western Blotting (WB), Immunohistochemistry (IHC), Immunofluorescence (IF), ELISA
- Kreuzreaktivität
- Human, Maus
- Aufreinigung
- Antibodies were produced by immunizing rabbits with synthetic peptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific peptide.
- Immunogen
- Peptide sequence around aa.244~248/257~261/218~222 (T-A-S-E-P) derived from Human HDAC4/HDAC5/HDAC9.
- Isotyp
- IgG
-
-
- Applikationshinweise
- WB:1:500-1:1000, IHC:1:50-1:200, IF:1:100-1:200,
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Buffer
- Supplied at 1.0 mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol.
- Konservierungsmittel
- Sodium azide
- Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Lagerung
- -20 °C,-80 °C
- Informationen zur Lagerung
- Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
- Target
- HDAC4/HDAC5/HDAC9 (HDAC4,HDAC5,HDAC9)
- Andere Bezeichnung
- HDAC4/HDAC5/HDAC9 (HDAC4/HDAC5/HDAC9 Produkte)
- Synonyme
- AHO3 antikoerper, BDMR antikoerper, HA6116 antikoerper, HD4 antikoerper, HDAC-4 antikoerper, HDAC-A antikoerper, HDACA antikoerper, histone deacetylase 4 antikoerper, HDAC4 antikoerper
- Hintergrund
-
Background:
Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. Involved in muscle maturation via its interaction with the myocyte enhancer factors such as MEF2A, MEF2C and MEF2D.
Cress, W.D. and Seto, E. (2000) J Cell Physiol 184, 1-16.
Vigushin, D.M. and Coombes, R.C. (2004) Curr. Cancer Drug Targets 4, 205-218.
Marmorstein, R. (2001) Cell Mol Life Sci 58, 693-703.
Thiagalingam, S. et al. (2003) Ann. N.Y. Acad. Sci. 983, 84-100.Aliases: HD4/HD5/HD9
- UniProt
- P56524, Q9UQL6, Q9UKV0
-